A Diagnostics & Imaging Week

Proteome Systems (Sydney, Australia) reported the closing of a private placement totaling A $2.5 million. The company will issue 23,809,524 shares at A$0.105 per share. Participants in the placement include Oppenheimer Funds and other U.S. and Australian investors.

Proceeds are being allocated to maintain development timelines for the company's two lead diagnostic programs: a rapid point-of-care test for tuberculosis and an on-site test for determining wheat quality and thus pricing.

Foster Stockbroking has been appointed as the arranger of the placement.

Proteome is a diagnostics company with expertise in biomarker discovery and diagnostic test development for respiratory and infectious diseases.

Thee company is developing the test for active tuberculosis in collaboration with BD (Becton, Dickinson and Co.; Franklin Lakes, New Jersey).

Bioheart (Sunrise, Florida), a company committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and cardiovascular diseases, reported the receipt of a $1 million unsecured loan from Rogers Telecommunications Limited.

This loan is payable upon the later of three months or Bioheart's repayment of its loan from BlueCrest Capital. In addition, under certain circumstances, the company may be permitted to pay outstanding interest and principal in shares of its common stock.

The company said the loan will be used for its ongoing clinical and business operations, as it continues to actively pursue additional investment support.

"We hope to soon introduce intelligent devices that offer synergies with our clinical therapies and provide critical at-home monitoring of these patients," said Chairman/CEO Howard Leonhardt.

Bioheart recently announced its plan to enter the device market as a complement to its MyoCell clinical therapy program, which targets patients with congestive heart failure.

Earlier this month, the company said it planned to acquire Medicalgorithmics (Warsaw, Poland) and the worldwide rights to the PocketECG, a real-time wireless beat-to-beat, intelligent heart monitor and diagnostic system, designed for long-term, fully-automated ECG arrhythmia and AFib analysis.

In July, the company reported that it secured worldwide non-exclusive distribution rights to the Bioheart 3370 heart failure monitor, an interactive at-home intelligent device designed specifically to improve available healthcare to patients outside hospitals who are suffering from heart failure.